linagliptin


Also found in: Medical, Wikipedia.

lin·a·glip·tin

 (lĭn′ə-glĭp′tn)
n.
An oral hypoglycemic drug, C25H28N8O2, used to treat type 2 diabetes.

[lina-, of unknown origin + -gliptin, hypoglycemic drug suffix; see saxagliptin.]
Mentioned in ?
References in periodicals archive ?
RIDGEFIELD, Conn, and INDIANAPOLIS, June 10, 2019 /PRNewswire/--Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced detailed findings from the CAROLINA[R] trial demonstrating that Tradjenta[R] (linagliptin) did not increase cardiovascular risk compared with glimepiride in adults with type 2 diabetes and cardiovascular risk.
- German pharmaceutical company Boehringer Ingelheim and US-based Eli Lilly and Company (NYSE: LLY) have released full data from the CAROLINA trial demonstrating that Trajenta (linagliptin) did not increase cardiovascular risk compared to glimepiride in adults with type 2 diabetes and cardiovascular risk, the company said.
The medications, which include sitagliptin (Januvia) and linagliptin (Tradjenta), are used to treat patients with T2DM who are inadequately controlled by first-line treatments.
In a previous study,[5] the ability of linagliptin (5 mg/d) to lower albuminuria in addition to inhibiting the renin-angiotensin-aldosterone system (RAAS) in humans was analyzed by pooling data from four similarly designed, 24-week, randomized, double-blind, placebo-controlled, Phase III trials.[10],[11],[12],[13] The results showed that the UACR at week 24 was reduced by 32% in the patients treated with linagliptin and RAAS inhibition, compared with 6% treated with placebo and RAAS inhibition.
In the DPP-4 inhibitor group, most exposures (49.7%) were to sitagliptin, 18.9% were to linagliptin, 10.4% were to saxagliptin, and the remaining exposures were to alogliptin, gemigliptin, teneligliptin, anagliptin, evogliptin, and trelagliptin (0.1%-4.7%).
CARMELINA, the "CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk" trial, met its primary endpoint, defined as time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, with Tradjenta demonstrating similar cardiovascular safety compared with placebo, reported Boehringer Ingelheim and Eli Lilly.
The medical terms (MeSH) used were the following: sodium-glucose cotransporter-2 OR SGLT2 OR empagliflozin OR canagliflozin OR dapagliflozin OR DPP-4 OR dipeptidyl peptidase-4 inhibitors OR sitagliptin OR saxagliptin OR vildagliptin OR linagliptin OR gemigliptin OR canagliptin OR teneligliptin OR alogliptin OR trelagliptin OR omarigliptin OR evogliptin OR dutogliptin OR GLP-1 OR glucagon-like peptide-1 OR exenatide OR lixisenatide OR dulaglutide OR liraglutide OR semaglutide AND endothelial function OR arterial stiffness OR flow-mediated dilation OR pulse wave velocity.
Hence, the present study was planned to evaluate wound healing property of linagliptin, saxagliptin, sitagliptin, and vildagliptin on excised wounds in non-diabetic Wistar albino rats.
Jentadueto XR is a prescription medicine that contains two diabetes medicines, linagliptin and metformin.
Healthcare company Eli Lilly and Company (NYSE:LLY) reported on Tuesday the receipt of approval from the US Food and Drug Administration (FDA) for once-daily Jentadueto XR (linagliptin and metformin hydrochloride extended-release) tablets for the treatment of type 2 diabetes (T2D) in adults.
The DPP-IV inhibitors approved in the United States are alogliptin (Nesina), linagliptin (Trajenta), saxagliptin (Onglyza), and sitagliptin (Januvia).